Ovarian cancer: state of the art and future directions in translational research

Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University ofPennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer.Meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities INDICE: From the contents Ovarian Cancer Detection and Pathogenesis.- 1. Potential and limitations in early diagnosis of Ovarian cancer.- 2.- SMRP and HE4 as biomarker for Ovarian carcinoma.- 3.- Classification of Ovarian cancer: A genomic analysis.- 4. Epigenetic markers of ovarian cancer.- Role of geneticpolymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.- 6.- MicroRNA in human cancer: One step forward in diagnosis and treatment.- 7.- Ovarian carcinogenesis, an alternative hypotheses.- 8.- BRCA1 induced Ovarian oncogenesis.- 9.- Role of p53 andRb in ovarian cancer.- 10.- Ovulatory factor in ovarian carcinogenesis.- Ovarian Cancer Therapeutics.- 11.- Gynecologic Oncology group trials in Ovarian Cancer.- 12.- Platinum Combinations for frontline chemotherapy of advanced ovarian carcinoma.- 13.- Intraperitoneal chemotherapy of Ovarian Cancer.- 14.- Ovarian cancer- can we reverse drug resistance?

• ISBN: 978-0-387-68966-1
• Editorial: Springer
• Encuadernacion: Cartoné
• Páginas: 330
• Fecha Publicación: 01/04/2008
• Nº Volúmenes: 1
• Idioma: Inglés